BACKGROUND AND OBJECTIVES: Hepcidin, the principal regulator of iron homeostasis, may play a critical role in the response of patients with anemia to iron and erythropoiesis-stimulating agent therapy; however, the contribution of hepcidin to iron maldistribution and anemia in hemodialysis (HD) patients and the ability of HD to lower serum hepcidin levels have not been fully characterized. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We measured serum hepcidin using a competitive ELISA in 30 pediatric and 33 adult HD patients. In addition, we determined serum hepcidin kinetics and calculated hepcidin clearance by measuring serum hepcidin before, during, and after HD in eight pediatric and six adult patients. RESULTS: Hepcidin was significantly increased in pediatric (median 240.5 ng/ml) and adult HD patients (690.2 ng/ml) when compared with their respective control subjects (pediatric 25.3 ng/ml, adult 72.9 ng/ml). Multivariate regression analysis showed that serum hepcidin was independently predicted by ferritin and high-sensitivity C-reactive protein in the pediatric group and ferritin, percentage of iron saturation, and high-sensitivity C-reactive protein in the adult group. Hepcidin levels decreased after dialysis from 532 +/- 297 to 292 +/- 171 ng/ml. Hepcidin clearance by HD was 141 +/- 40 and 128 +/- 44 ml/min in pediatric and adult patients, respectively (NS). CONCLUSIONS: These findings suggest that hepcidin may mediate the negative effects of inflammation on both disordered iron metabolism and erythropoiesis in HD patients and that intensification of HD could be used therapeutically to reduce hepcidin concentrations and thereby improve erythropoiesis-stimulating agent responsiveness.
BACKGROUND AND OBJECTIVES:Hepcidin, the principal regulator of iron homeostasis, may play a critical role in the response of patients with anemia to iron and erythropoiesis-stimulating agent therapy; however, the contribution of hepcidin to iron maldistribution and anemia in hemodialysis (HD) patients and the ability of HD to lower serum hepcidin levels have not been fully characterized. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We measured serum hepcidin using a competitive ELISA in 30 pediatric and 33 adult HDpatients. In addition, we determined serum hepcidin kinetics and calculated hepcidin clearance by measuring serum hepcidin before, during, and after HD in eight pediatric and six adult patients. RESULTS:Hepcidin was significantly increased in pediatric (median 240.5 ng/ml) and adult HDpatients (690.2 ng/ml) when compared with their respective control subjects (pediatric 25.3 ng/ml, adult 72.9 ng/ml). Multivariate regression analysis showed that serum hepcidin was independently predicted by ferritin and high-sensitivity C-reactive protein in the pediatric group and ferritin, percentage of iron saturation, and high-sensitivity C-reactive protein in the adult group. Hepcidin levels decreased after dialysis from 532 +/- 297 to 292 +/- 171 ng/ml. Hepcidin clearance by HD was 141 +/- 40 and 128 +/- 44 ml/min in pediatric and adult patients, respectively (NS). CONCLUSIONS: These findings suggest that hepcidin may mediate the negative effects of inflammation on both disordered iron metabolism and erythropoiesis in HDpatients and that intensification of HD could be used therapeutically to reduce hepcidin concentrations and thereby improve erythropoiesis-stimulating agent responsiveness.
Authors: George Papanikolaou; Michalis Tzilianos; John I Christakis; Dionisios Bogdanos; Konstantina Tsimirika; Julie MacFarlane; Y Paul Goldberg; Nikos Sakellaropoulos; Tomas Ganz; Elizabeta Nemeth Journal: Blood Date: 2005-01-25 Impact factor: 22.113
Authors: Elizabeta Nemeth; Marie S Tuttle; Julie Powelson; Michael B Vaughn; Adriana Donovan; Diane McVey Ward; Tomas Ganz; Jerry Kaplan Journal: Science Date: 2004-10-28 Impact factor: 47.728
Authors: Hilde P E Peters; Coby M M Laarakkers; Dorine W Swinkels; Jack F M Wetzels Journal: Nephrol Dial Transplant Date: 2009-10-23 Impact factor: 5.992
Authors: Elizabeta Nemeth; Seth Rivera; Victoria Gabayan; Charlotte Keller; Sarah Taudorf; Bente K Pedersen; Tomas Ganz Journal: J Clin Invest Date: 2004-05 Impact factor: 14.808
Authors: George O Ting; Carl Kjellstrand; Terri Freitas; Brian J Carrie; Shahrzad Zarghamee Journal: Am J Kidney Dis Date: 2003-11 Impact factor: 8.860
Authors: Meredith A Atkinson; Stephen P Juraschek; Michael S Bertenthal; Barbara Detrick; Susan L Furth; Edgar R Miller Journal: Pediatr Nephrol Date: 2016-12-24 Impact factor: 3.714
Authors: Meredith A Atkinson; Ji Young Kim; Cindy N Roy; Bradley A Warady; Colin T White; Susan L Furth Journal: Pediatr Nephrol Date: 2014-11-08 Impact factor: 3.714